Wasuwanich P, So JM, Chakrala TS, Chen J, Motaparthi K. Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome. JAAD Int. 2023;13:17–25.

Article  PubMed  PubMed Central  Google Scholar 

Monnet P, Rodriguez C, Gaudin O, Cirotteau P, Papouin B, Dereure O, et al. Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases. J Eur Acad Dermatol Venereol. 2021;35(7):1569–76.

Article  CAS  PubMed  Google Scholar 

Chaby G, Ingen-Housz-Oro S, De Prost N, Wolkenstein P, Chosidow O, Fardet L. Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and patients’ characteristics. J Am Acad Dermatol. 2019;80(5):1453–5.

Article  PubMed  Google Scholar 

Welfringer-Morin A, Bataille P, Drummond D, Bellon N, Ingen-Housz-Oro S, Bonigen J, et al. Comparison of idiopathic and drug-induced epidermal necrolysis in children. Br J Dermatol. 2023;189(5):631–3.

Article  PubMed  Google Scholar 

Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States Adults. J Invest Dermatol. 2016;136(7):1387–97.

Article  CAS  PubMed  Google Scholar 

Liotti L, Caimmi S, Bottau P, Bernardini R, Cardinale F, Saretta F, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2019;90(3-S):52–60.

CAS  PubMed  Google Scholar 

Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.

Article  CAS  PubMed  Google Scholar 

Pan CX, Hussain SH. Recurrent reactive infectious mucocutaneous eruption: a retrospective cohort study. J Am Acad Dermatol. 2023;89(2):361–4.

Article  PubMed  Google Scholar 

Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: a multicenter case series. J Am Acad Dermatol. 2020;83(5):1475–7.

Article  PubMed  Google Scholar 

Reschke R, Mockenhaupt M, Simon JC, Ziemer M. Severe bullous skin eruptions on checkpoint inhibitor therapy—in most cases severe bullous lichenoid drug eruptions. J Dtsch Dermatol Ges. 2019;17(9):942–8.

Article  PubMed  Google Scholar 

Satoh TK, Neulinger MM, Stadler PC, Aoki R, French LE. Immune checkpoint inhibitor-induced epidermal necrolysis: a narrative review evaluating demographics, clinical features, and culprit medications. J Dermatol. 2024;51(1):3–11.

Article  CAS  PubMed  Google Scholar 

Marks ME, Botta RK, Abe R, Beachkofsky TM, Boothman I, Carleton BC, et al. Updates in SJS/TEN: collaboration, innovation, and community. Front Med (Lausanne). 2023;10:1213889.

Article  PubMed  PubMed Central  Google Scholar 

Bettuzzi T, Hoisnard L, Beytout Q, Ingen-Housz-Oro S, Sbidian E. Validation of an algorithm to identify epidermal necrolysis on a medico-administrative database. J Invest Dermatol. 2023. https://doi.org/10.1016/j.jid.2023.09.274.

Article  PubMed  Google Scholar 

Roberson ML. Precision in language regarding geographic region of origin in severe cutaneous adverse drug reaction research. JAMA Dermatol. 2024;160(5):534.

Article  PubMed  Google Scholar 

Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543–6.

Article  CAS  PubMed  Google Scholar 

Peter J, Choshi P, Lehloenya RJ. Drug hypersensitivity in HIV infection. Curr Opin Allergy Clin Immunol. 2019;19(4):272–82.

Article  PubMed  PubMed Central  Google Scholar 

Alajaji A, Chandra Shekaran J, Mohammed Aldhabbah O, Alhindi HA, Almazyad NS, Aljutayli ZA, et al. Toxic Epidermal Necrolysis (TEN)/Stevens-Johnson Syndrome (SJS) Epidemiology and Mortality Rate at King Fahad Specialist Hospital (KFSH) in Qassim Region of Saudi Arabia: a retrospective study. Dermatol Res Pract. 2020;2020:7524726.

Article  PubMed  PubMed Central  Google Scholar 

Chiu YM, Chiu HY. Lifetime risk, life expectancy, loss-of-life expectancy and lifetime healthcare expenditure for Stevens-Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019. Br J Dermatol. 2023;189(5):553–60.

Article  PubMed  Google Scholar 

Guzman AK, Zhang M, Kwatra SG, Kaffenberger BH. Predictors of 30-day readmission in Stevens-Johnson syndrome and toxic epidermal necrolysis: a cross-sectional database study. J Am Acad Dermatol. 2020;82(2):303–10.

Article  PubMed  Google Scholar 

Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A multicenter retrospective study of 377 adult patients from the United States. J Invest Dermatol. 2018;138(11):2315–21.

Article  CAS  PubMed  Google Scholar 

Wang L, Varghese S, Bassir F, Lo YC, Ortega CA, Shah S, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed/MEDLINE case reports from 1980 to 2020. Front Med (Lausanne). 2022;9: 949520.

Article  PubMed  PubMed Central  Google Scholar 

Jha KK, Chaudhary DP, Rijal T, Dahal S. Delayed Stevens-Johnson syndrome secondary to the use of lamotrigine in bipolar mood disorder. Indian J Psychol Med. 2017;39(2):209–12.

Article  PubMed  PubMed Central  Google Scholar 

Kim EJ, Lim H, Park SY, Kim S, Yoon SY, Bae YJ, et al. Rapid onset of Stevens-Johnson syndrome and toxic epidermal necrolysis after ingestion of acetaminophen. Asia Pac Allergy. 2014;4(1):68–72.

Article  PubMed  PubMed Central  Google Scholar 

Poulsen VO, Nielsen J, Poulsen TD. Rapidly developing toxic epidermal necrolysis. Case Rep Emerg Med. 2013;2013: 985951.

PubMed  PubMed Central  Google Scholar 

Schunkert EM, Shah PN, Divito SJ. Skin resident memory T cells may play critical role in delayed-type drug hypersensitivity reactions. Front Immunol. 2021;12: 654190.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng L. Current pharmacogenetic perspective on Stevens-Johnson Syndrome and toxic epidermal necrolysis. Front Pharmacol. 2021;12: 588063.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162(5):1515–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490–3.

Article  CAS  PubMed  Google Scholar 

Morel E, Escamochero S, Cabanas R, Diaz R, Fiandor A, Bellon T. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol. 2010;125(3):703–10 (10 e1-10 e8).

Article  CAS  PubMed  Google Scholar 

Saito N, Qiao H, Yanagi T, Shinkuma S, Nishimura K, Suto A, et al. An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci Transl Med. 2014;6(245):245ra95.

Article  PubMed  Google Scholar 

Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343–50.

Article  CAS  PubMed